Evidence map›Paper›PMID 32382051›Full record

ReviewNature reviews. Disease primers2020

Immune-related adverse events of checkpoint inhibitors.

Manuel Ramos-Casals, Julie R Brahmer, Margaret K Callahan, Alejandra Flores-Chávez, Niamh Keegan, Munther A Khamashta, Olivier Lambotte, Xavier Mariette, Aleix Prat, Maria E Suárez-Almazor

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07249060 (Interferon Signature in Cancer Patients Treated With Anti-CTLA-4 and Anti-PD-1/PD-L1 Therapies), which is not on this map. Cited by 878 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
878citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07249060 recruitingnot on this mapstarted 2024, after this paper: background citation

Interferon Signature in Cancer Patients Treated With Anti-CTLA-4 and Anti-PD-1/PD-L1 Therapies: A Multicenter, Prospective, Observational Cohort Study Comparing Cancer Patients and Non-Cancer Patients With Systemic Autoimmune Diseases

Typeobservational_patient_registrySponsorHospital Universitario ArabaRan2024 to 2026Enrolled300ConditionsImmune-Related Adverse Events, Lupus Erythematosus, Systemic, Sjogren Syndrome, Systemic Sclerosis (SSc)ArmsImmune Checkpoint Inhibitors
3 · Its place in the literature

Who cites it

878 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  13. Type 3 Autoimmune Pancreatitis: What Do We Know So Far?Digestive diseases and sciences · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

818 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manuel Ramos-CasalsDepartment of Autoimmune Diseases, ICMiD, Barcelona, Spain. mramos@clinic.cat.
Julie R BrahmerDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Margaret K CallahanMelanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alejandra Flores-ChávezLaboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain.
Niamh KeeganMelanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Munther A KhamashtaLupus Clinic, Rheumatology Department, Dubai Hospital, Dubai, UAE.
Olivier LambotteAPHP Médecine Interne/Immunologie Clinique, Hôpital Bicêtre, Paris, France.
Xavier MarietteUniversité Paris-Saclay, INSERM, CEA, Centre de recherche en Immunologie des infections virales et des maladies auto-immunes; AP-HP. Université Paris-Saclay, Hôpital Bicêtre, Rheumatology Department, Le Kremlin Bicêtre, Paris, France.
Aleix PratTranslational Genomic and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Maria E Suárez-AlmazorSection of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Cancer immunotherapies have changed the landscape of cancer treatment during the past few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and CTLA-4, are increasingly used for certain cancers; however, this increased use has resulted in increased reports of immune-related adverse events (irAEs). These irAEs are unique and are different to those of traditional cancer therapies, and typically have a delayed onset and prolonged duration. IrAEs can involve any organ or system. These effects are frequently low grade and are treatable and reversible; however, some adverse effects can be severe and lead to permanent disorders. Management is primarily based on corticosteroids and other immunomodulatory agents, which should be prescribed carefully to reduce the potential of short-term and long-term complications. Thoughtful management of irAEs is important in optimizing quality of life and long-term outcomes.

Indexed as

Antibodies, MonoclonalAutoantibodiesB7-H1 AntigenBiomarkersCTLA-4 AntigenDisease ManagementDrug-Related Side Effects and Adverse ReactionsGlucocorticoidsHumansImmune Checkpoint InhibitorsImmunologic FactorsProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalAutoantibodiesB7-H1 AntigenBiomarkersCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanGlucocorticoidsImmune Checkpoint InhibitorsImmunologic FactorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID32382051
PMCPMC9728094

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.